160 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Apr 24
Report of Foreign Private Issuer
8:02am
trial is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize the safety and tolerability … -blind, randomized, placebo-controlled stage, which the Company expects to initiate following the completion of the safety run-in stage
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
8:00am
of Health (IMOH) in January.
The Phase I/II multi-center trial is composed of two stages. The first stage is a safety run-in, open-label dose escalation … phase to characterize the safety and tolerability of Allocetra™ injections to the target knee in order to identify the dose and injection regimen
6-K
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
” and “Safety” in such press release is incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
from the sepsis Phase II study (NCT# NCT04612413)
In accordance with the study protocol, the safety and efficacy topline analysis includes sequential … in other patient subgroups.
Safety: Stand-alone and placebo-compared analysis across all sepsis patient subgroups and risk categories demonstrated
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
Randomized/controlled, 160 patients , enrolling Randomized, controlled, Phase II, 120 patients, ongoing. Efficacy stage completed; safety follow - up … / trials Administration method Safety Efficacy 1 completed trial: 2 completed trials: Compassionate case Systemic administration Local injection
6-K
EX-99.1
00d6 s5x3j8c8
7 Feb 24
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
8:02am
6-K
ppr3tc
22 Jan 24
Report of Foreign Private Issuer
8:00am
6-K
twpa1amhi5r9a56tv3
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
36mp2zw
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
yatvy9
20 Dec 23
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
8:01am
6-K
EX-99.2
4xij4cpo0xf22qh1qvv1
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
7ni2csrnz7w
7 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
dutfrjc0 z8p
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
yvg1idqr2kt opqcs
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
3xnf228mqdzs9axc3iuc
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
q7vpb 4ve
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
xttleez i9rgiudw
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
79l hchkrqp
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
EX-99.1
e20u59qk lcd5atm8pq4
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.2
mbz43c9jcjeqoglecx4t
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm